Meet the Expert

Susan S. VanBeuge, DNP, APRN, FNP-BC
Susan S. VanBeuge, DNP, APRN, FNP-BC
Professor-in-Residence, Nursing Department
University of Nevada

Dr. Susan VanBeuge is a professor-in-residence, teaching across the curriculum in the School of Nursing. Her research interests include cancer survivorship, interprofessional collaboration, health care policy, endocrinology, and health promotion. Dr. VanBeuge has appeared in peer-reviewed journals and other publications, and she has presented research findings about topics related to clinical areas in endocrinology, interprofessional collaboration, and health care policy during national conferences and meetings. Dr. VanBeuge serves the community as an RN member of the Nevada State Board of Nursing, and currently serving as the Board President. Dr. VanBeuge is an elected member of the National Council State Boards of Nursing (NCSBN) Board of Directors, serving as the Area 1 Director from 2021-2023. Dr. VanBeuge serves as the Vice-Chair of the Nevada Primary Care Advisory Council and is member of the recruitment and retention committee. Dr. VanBeuge is also a fellow in the American Academy of Nursing (FAAN) and American Association of Nurse Practitioners (AANP). She is an active member and previous elected leader in the AANP, serving as the Nevada State Representative for two terms.

Susan S. VanBeuge, DNP, APRN, FNP-BC is a paid consultant to Acella Pharmaceuticals, LLC.

Note that DTE products, including NP Thyroid®, have not been reviewed by the FDA for safety or efficacy.

Important Risk Information

Drugs with thyroid hormone activity, alone or together with other therapeutic agents, have been used for the treatment of obesity. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.
  • NP Thyroid® is contraindicated in patients with uncorrected adrenal insufficiency, untreated thyrotoxicosis, and hypersensitivity to any component of the product.
  • In the elderly and in patients with cardiovascular disease, NP Thyroid® should be used with greater caution than younger patients or those without cardiovascular disease.
  • Use of NP Thyroid® in patients with diabetes mellitus or adrenal cortical insufficiency may worsen the intensity of their symptoms.
  • The therapy of myxedema coma requires simultaneous administration of glucocorticoids.
  • Concomitant use of NP Thyroid® with oral anticoagulants alters the sensitivity of oral anticoagulants. Prothrombin time should be closely monitored in thyroid-treated patients on oral anticoagulants.
  • In infants, excessive doses of NP Thyroid® may produce craniosynostosis.
  • Partial loss of hair may be experienced by children in the first few months of therapy but is usually transient.
  • Adverse reactions associated with NP Thyroid® therapy are primarily those of hyperthyroidism due to therapeutic overdosage.
  • Many drugs and some laboratory tests may alter the therapeutic response to NP Thyroid®. In addition, thyroid hormones and thyroid status have varied effects on the pharmacokinetics and actions of other drugs. Administer at least 4 hours before or after drugs that are known to interfere with absorption. Evaluate the need for dose adjustments when regularly administering within one hour of certain foods that may affect absorption.
  • NP Thyroid® should not be discontinued during pregnancy, and hypothyroidism diagnosed during pregnancy should be promptly treated.


NP Thyroid® (thyroid tablets, USP) is a prescription medicine that is used to treat a condition called hypothyroidism from any cause, except for cases of temporary hypothyroidism, which is usually associated with an inflammation of the thyroid (thyroiditis). It is meant to replace or supplement a hormone that is usually made by your thyroid gland.

NP Thyroid® is also used in the treatment and prevention of normal functioning thyroid goiters, such as thyroid nodules, Hashimoto’s thyroiditis, multinodular goiter, and in the management of thyroid cancer.

Revised 10/2023